reMYND

Foundation date

07/02/2002

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

reMYND actively drives the development of disease modifying treatments against Alzheimer’s disease (AD), Parkinson’s disease (PD), and diabetes, either as a Contract Research Organisation (CRO) or through its own drug discovery & development (DDD).

Upcoming events

Latest news

  • Mithra appoints experienced life sciences executive Christian Homsy* as Chairman

    19 hours ago

  • Oxurion reaches enrollment target in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema

    Friday May 26th 2023

  • How garbage disposal clogs in cells can lead to Alzheimer’s

    Friday May 26th 2023

Jobs by reMYND